3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Whole-Brain Radiotherapy
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Ovarian Neoplasms
1
Nasopharyngeal Carcinoma
1
Lung Neoplasms
1
Leiomyosarcoma
1
Fallopian Tube Neoplasms
1
Extensive Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced Renal Cancer
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Doxorubicin
8
Ifosfamide
6
Radiotherapy
4
Dacarbazine
3
Trabectedin
2
Filgrastim
2
pegfilgrastim
1
olaratumab
1
indolepropanol phosphate
1
anlotinib
1
Watchful Waiting
1
Tablets
1
Surgical Procedures, Operative
1
Rosuvastatin Calcium
1
Radiotherapy, Conformal
1
PM 01183
1
Observation
1
Neoadjuvant Therapy
1
Midazolam
1
Etoposide
1
Digoxin
1
Diathermy
1
Combined Modality Therapy
1
Chemotherapy, Adjuvant
1
ADI PEG20
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leiomyosarcoma
×
anlotinib
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled